Cough and angioedema in patients receiving angiotensin-converting enzyme inhibitors. Are they always attributable to medication?;Tos y angioedema en pacientes tratados con inhibidores de la enzima convertidora de la angiotensina: ¿siempre es culpable la medicación?

Revista Argentina de Cardiologia

Volumn 79, Issue 2, 2011, Pages 157-163

  Zamora, Sebastián García ^a   Parodi, Roberto ^b  

^a UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^b FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

Author keywords

Angioedema; Cough; Hypertension; Treatment

Indexed keywords

ADRENALIN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHISTAMINIC AGENT; CAPTOPRIL; CILAZAPRIL; CROMOGLYCATE DISODIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FERROUS SULFATE; HYDROCHLOROTHIAZIDE; IMIDAPRIL; INDOMETACIN; NIFEDIPINE; OMAPATRILAT; PERINDOPRIL; PICOTAMIDE; SULINDAC; THEOPHYLLINE;

ANGIONEUROTIC EDEMA; COUGHING; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; ETHNIC DIFFERENCE; ETHNICITY; HUMAN; HYPERTENSION; INCIDENCE; PRACTICE GUIDELINE; RASH; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE;

EID: 80052662785     PISSN: 00347000     EISSN: 18503748     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Irwin RS, Baumann MH, Bolser DC, Boulet LP, Braman SS, Brightling CE, et al; American College of Chest Physicians (ACCP). Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest 2006;129:1S-23S.
2. Chung KF, Pavord ID. Prevalence, pathogenesis, and causes of chronic cough. Lancet 2008;371:1364-74.
3. Irwin RS, Madison JM. The diagnosis and treatment of cough. N Engl J Med 2000;343:1715-21.
4. Morice AH, Kastelik JA. Cough. 1: Chronic cough in adults. Thorax 2003;58:901-7.
5. López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 2004;25:1454-70.
6. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 2006;129:169S-173S.
7. Bicket DP. Using ACE inhibitors appropriately. Am Fam Physician 2002;66:461-8.
8. Parish RC, Miller LJ. Adverse effects of angiotensin converting enzyme (ACE) inhibitors. An update. Drug Saf 1992;7:14-31.
9. Alderman CP. Adverse effects of the angiotensin-converting enzyme inhibitors. Ann Pharmacother 1996;30:55-61.
10. Lombardi C, Crivellaro M, Dama A, Senna G, Gargioni S, Passalacqua G. Are physicians aware of the side effects of angiotensin-converting enzyme inhibitors?: a questionnaire survey in different medical categories. Chest 2005;128:976-9.
11. Ratnapalan S, Koren G. Taking ACE inhibitors during pregnancy. Is it safe? Can Fam Physician 2002;48:1047-9.
12. Ray JG, Vermeulen MJ, Koren G. Taking ACE inhibitors during early pregnancy: is it safe? Can Fam Physician 2007;53:1439-40.
13. Sebastian JL, McKinney WP, Kaufman J, Young MJ. Angiotensin-converting enzyme inhibitors and cough. Prevalence in an outpatient medical clinic population. Chest 1991;99:36-9.
14. Mukae S, Aoki S, Itoh S, Iwata T, Ueda H, Katagiri T. Bradykinin B(2) receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough. Hypertension 2000;36:127-31.
15. Dykewicz MS. Cough and angioedema from angiotensin-converting enzyme inhibitors: new insights into mechanisms and management. Curr Opin Allergy Clin Immunol 2004;4:267-70.
16. McGarvey LP, Polley L, MacMahon J. Common causes and current guidelines. Chron Respir Dis 2007;4:215-23.
17. Reisin L, Schneeweiss A. Spontaneous disappearance of cough induced by angiotensin-converting enzyme inhibitors (captopril or enalapril). Am J Cardiol 1992;70:398-9.
18. Reisin L, Schneeweiss A. Complete spontaneous remission of cough induced by ACE inhibitors during chronic therapy in hypertensive patients. J Hum Hypertens 1992;6:333-5.
19. Tumanan-Mendoza BA, Dans AL, Villacin LL, Mendoza VL, Rellama-Black S, Bartolome M, et al. Dechallenge and rechallenge method showed different incidences of cough among four ACE-Is. J Clin Epidemiol 2007;60:547-53. Epub 2006 Oct 25.
20. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
21. Cicardi M, Zingale LC, Bergamaschini L, Agostoni A. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med 2004;164:910-3.
22. Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension 2008;51:1624-30. Epub 2008 Apr 14.
23. Weber MA, Messerli FH. Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk. Hypertension 2008;51:1465-7. Epub 2008 Apr 14.
24. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004;17:103-11.
25. Kostis JB, Kim HJ, Rusnak J, Casale T, Kaplan A, Corren J, et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med 2005;165:1637-42.
26. Reshef A, Leibovich I, Goren A. Hereditary angioedema: new hopes for an orphan disease. Isr Med Assoc J 2008;10:850-5.
27. Lee SC, Park SW, Kim DK, Lee SH, Hong KP. Iron supplementation inhibits cough associated with ACE inhibitors. Hypertension 2001;38:166-70.
28. Lev I, Rian AJ. Iron supplementation in ACE inhibition as a treatment for cough: is it really inoffensive? Hypertension 2001;38:E38-8.
29. Mackay FJ, Pearce GL, Mann RD. Cough and angiotensin II receptor antagonists: cause or confounding? Br J Clin Pharmacol 1999;47:111-4.
30. Fuchs SA, Koopmans RP, Guchelaar HJ, Brodie-Meijer CC, Meyboom RH. Are angiotensin II receptor antagonists safe in patients with previous angiotensin-converting enzyme inhibitor-induced angioedema? Hypertension 2001;37:E1.
31. Dickstein K, Kjekshus J. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction. The OPTIMAAL trial design. Am J Cardiol 1999;83:477-81.
32. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.
33. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.
34. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
35. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
36. Barnett A. Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial. J Am Soc Nephrol 2006;17:S132-5.
37. García Zamora S, Parodi R. Tratamiento antihipertensivo, nuevos casos de diabetes y otras controversias. Rev Méd Rosario 2008;74:135-47.
38. Grosse A, Coviello A. El fenómeno placebo en el tratamiento de la hipertensión arterial. Boletín del Consejo Argentino de Hipertensión Arterial-Sociedad Argentina de Cardiología. 2004;5.